Replies to post #279077 on Amarin Corp Plc (AMRN)

[funnygi2]

AMRN would have 414 million shares outstanding if all options currently granted are exercised.
$15,000,000,000 divided into 414,000,000 is approximately $36.23 per share

[zmanindc]

Let’s see if this is an orchestrated run-up to sell 7.50 and 8.00 calls for 6/08 only to drop them worthless at expiration.

[jessellivermore]

Jas...

Quote: "The general market will eventually look at AMRN as a value stock, and it's valuation of $3bn market cap is a fire-sale due to appeals over-hang; however, standalone Europe valuation is close to $15bn or ruffly $50 PPS."

Now I think you are thinking like a player.....

The AC is a total "crap shoot"...The real issue here is that Off Label scrips are perfect legal and widely used..The iniquity (unfairness) here is the pretty much close to worthless MARINE indication can be used to shoe horn Marine into the R-I indication.
I am surprised that Amarin has not taken a close look at the MARINE label as a dodge for the patent validity..

Marine Label --------------------------INDICATIONS AND USAGE-----------------------------­
VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an
adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe
(≥500 mg/dL) hypertriglyceridemia. (1)
Limitations of Use:
•The effect of VASCEPA on the risk for pancreatitis in patients with severe
hypertriglyceridemia has not been determined. (1)
•The effect of VASCEPA on cardiovascular mortality and morbidity in
patients with severe hypertriglyceridemia has not been determined. (1)

"Has not been determined...

Compare this label with Lovaza..

Lovaza Label................INDICATIONS AND USAGE --------------------­
LOVAZA is a combination of ethyl esters of omega 3 fatty acids, principally
EPA and DHA, indicated as an adjunct to diet to reduce triglyceride (TG) levels
in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). (1)
Limitations of Use:
• The effect of LOVAZA on the risk for pancreatitis has not been
determined. (1)
• The effect of LOVAZA on cardiovascular mortality and morbidity has not been determined...

Maybe I am missing something here, but the Vascepa Marine label and Lovaza label for indications and usage are the same...

This may have escaped everyones' attention but it has some very significant consequences for the generics...Tier pricing is determined by the cheapest alternative and I believe generic Lovaza will be be able to undercut the generic Vascepa price..And keep in mind that even if generic V can be converted to off label R-I Vascepa..The generics have not won the right to sell the drug for the R-I indication..And if Lovaza can beat Gen Vs price then Gen V will be selling at a higher Tier (ie Tier 3 Or possibly Tier four 4)..And this real possibility could encourage the Generics to settle..as selling the drug without being able to convert to the R-I indication will not be be very profitable..

":>) JL

[jeebray]

why is stock at $7 then?

[sstyles]

Why do you think the generics' brief will be weak?